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Abstract
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened a Working Group on
the Microbiome in Cardiovascular, Pulmonary and Hematologic Health and Diseases from June 25, 2014, to June 26, 2014.
The Working Group’s central goal was to define what major microbiome research areas warranted additional study in the
context of heart, lung, and blood (HLB) diseases. The Working Group identified studies of the human virome a
key priority.
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Introduction
The Human Microbiome (http://hmpdacc.org/overview/
about.php, last accessed January 11, 2016) comprises the
bacteria, viruses, and other microorganisms living in as-
sociation with the human body [1–3]. To define what
major microbiome research areas warranted additional
study in the context of heart, lung, and blood (HLB)
diseases, the National Heart, Lung, and Blood Institute
(NHLBI) of the National Institutes of Health convened a
Working Group on the Microbiome in Cardiovascular,
Pulmonary and Hematologic Health and Diseases from
June 25, 2014, to June 26, 2014. The objectives of the
Working Group included: (1) evaluation of the current
state of knowledge on the role of microbiome in cardio-
vascular, pulmonary, or hematologic health and disease
outcomes, (2) assessment whether this knowledge can
be used to identify the means to modulate the micro-
biota or its dependent processes to prevent disease and
promote health, and (3) identification of next steps to
help move the research forward. The Working Group
identified studies of the human virome a key priority.
The composition of the human virome includes viruses
that infect human cells, ancient virus-derived elements
inserted in our chromosomes, and bacteriophages that
infect a broad array of bacteria that inhabit us. As a recent
report highlighted, there is a disparity relative to the need
in the level of support for virome research [4]. Despite ad-
vances in sequencing technology, there are still very few
studies addressing non-bacterial components of the micro-
biome including the virome [5]. Challenges include lack of
common markers for viruses in contrast to bacteria, the
heterogeneity of the virome elements, difficulties working
with low biomass samples, confounding by host DNA back-
ground, inadequate bioinformatic tools for analysis of the
virome, and a lack of robust and curated virome databases.
This report aims at summarizing the current state of the
science and examining the next steps in this exciting field.
Current status of human virome research
The description of the human virome, when compared to
the now well-described bacterial microbiome, is relatively
recent and rather limited. Currently, a few virome studies
suggest that viruses may have either beneficial or detrimen-
tal effects on human health, depending on their interactions
with the host, other viruses, and bacteria [6–16]. Studies
have shown that salivary, gastrointestinal, and respiratory
tract viromes are distinct, indicating that the local environ-
ment plays a fundamental role in shaping human viromes
[17]. These studies also suggest that these viruses may have
a role in helping shape the microbial diversity in the human
oral cavity [17]. Gut bacteria play a fundamental role in hu-
man health and have been implicated in a number of
pathophysiological processes, including obesity, inflamma-
tory bowel disease (IBD), and cardiovascular disease (CVD)
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[18]. Studies have suggested that regulation of microbial
diversity in the gastrointestinal tract and systemic circula-
tion by the virome could have far-reaching implications.
For example, it was observed that specific expansion of
Caudovirales (bacteriophages) in Crohn’s disease has been
associated with decreased bacterial diversity, supporting the
idea that the virome may contribute to intestinal inflamma-
tion and bacterial dysbiosis [19]. Abeles and Pride have
shown that the bacteriophages in the gut could affect the
bacterial flora that host them [20]. Hence, it is possible that
they could impact bacterial function as well. Tang and
Hazen have shown that a subset of gut bacteria are involved
in the formation of trimethylamine, a metabolite linked to
atherosclerosis, and it is possible that bacteriophages could
modulate this process [21].
A very limited number of studies have focused on the
virome of the lung and respiratory tract. Many respira-
tory infectious diseases are caused by bacteria and/or
viruses that live in a complex interactive environment
[22]. Disturbances of this environment by colonization
of new entry species can lead to overgrowth and inva-
sion of pathobionts (defined as “any potentially patho-
logical (disease-causing) organism which, under normal
circumstances, lives as a symbiont”), leading to disease.
Viral presence alters the host epithelium (first line of
host defense) rendering it more susceptible to bacterial
infection [23]. Indeed, research has suggested that re-
spiratory viruses and the consequent response of the in-
nate immune system could also drive the development
of asthma and chronic obstructive pulmonary disease
(COPD) [9]. Further, studies of the DNA virome within
the respiratory tract following lung transplantation shows
complex anellovirus populations in transplant recipients,
with multiple concurrent variants. These high anellovirus
loads correlated with dysbiotic bacterial communities in
allograft bronchoalveolar lavages. Although it has been
known for some time that long-term lung transplant out-
comes have been linked to prior infection with several
viruses, such as cytomegalovirus and community-acquired
respiratory viruses, this research example highlights the
importance and need to better understand the human
virome, as it may unravel unique factors and mechanisms
influencing both viral and bacterial microbiota that ultim-
ately may dictate disease outcomes [24].
Many viruses can persist in cells such as hematopoietic
cells and vascular endothelial cells, and such viruses can in-
fluence the host in profound ways independent of classical
viral disease [1, 25]. The immune system is continuously
stimulated by chronic systemic viruses, and this aspect of
host-microbiome interactions appears specific to the vir-
ome. The virome is considered one of the drivers of idio-
pathic systemic inflammation that has been linked to many
of the most severe public health problems, including
cardiovascular diseases [25]. Alternatively, some viruses
may be protective; for example, GB virus C or hepatitis
G virus (HGV) may have a protective effect against
human immunodeficiency virus (HIV)-associated dis-
ease [15]. Cytomegalovirus, a highly prevalent virus,
appears to promote recipient T cell immunity following
reduced-intensity T cell-depleted hematopoietic stem
cell (HSC) transplantation [16].
While these initial reports highlight the potential role of
the virome in health, resilience, and disease, the basic mo-
lecular and physiological mechanisms underlying these
effects remain largely unknown. Do viruses have a role in
cellular networks, cell-cell interactions, developmental
pathways, or interactions with commensal bacteria that
can potentiate or lead to disease, and if so what are the
molecular mechanisms? Do viral chromosomal insertions
contribute to host adaptation? Can specific viruses prime
our immune system and how? How do specific vascular
endothelial cell viromes affect the interactions between
the endothelium and blood elements? Are viruses involved
in normal cell homeostasis? Can they, through immune
and inflammatory mediators, explain some of the varia-
tions in phenotypes among persons sharing known genetic
mutations such as cystic fibrosis or sickle cell disease?
Limited studies have also shown the potential import-
ance of the human virome in the context of HIV infection.
Other than the protective effect of GB virus C as indicated
above [15], pathogenic simian immunodeficiency virus
infection appears to be associated with expansion of the
enteric virome and acquired immunodeficiency syndrome
(AIDS) alters the commensal plasma virome [26–28].
Recent work shows that the virome can chronically stimu-
late the immune system, potentiating ongoing inflamma-
tory processes [25]. HIV-infected adults have an excess
risk of cardiovascular, liver, kidney, bone, and neurologic
diseases. Many markers of inflammation are elevated in
HIV disease and strongly predictive of morbidity and
mortality. Understanding the role of the virome in in-
flammation could potentially permit the identification
of strategies to prevent or decrease the development of
comorbidities in HIV patients [29]. Research questions
of interest include: How does HIV interact with the rest
of the virome and the microbiome? What is the role of
genetic determinants in affecting the interactions between
HIV and the virome? What are the mechanisms by which
interactions between HIV and the virome contribute to
heart, lung, and blood co-morbidities as well as HIV
pathogenesis and chronic inflammation? What is the role
of the virome in heart, lung, and blood health as well as
other co-morbidities in the context of treatment of HIV
infection with anti-retroviral therapy?
What is next?
The NIH Human Microbiome Project (HMP) [30] has
allowed us to better appreciate the role of bacteria in
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human health and has also led to the realization of the
potential importance of the virome for heart, lung, and
blood health and resilience as well as diseases. The ad-
vances facilitated through HMP efforts, such as metage-
nomic sequencing and computational analysis of large
quantities of sequence data, can be leveraged for human
virome research. However, the unique challenges facing
virome research, such as the lack of a universal viral
molecular marker (similar to bacterial 16S rRNA) and
the heterogeneity of the virome elements, highlight the
need for focused special research efforts.
Specific recommendations from the NHLBI Working
Group on the Microbiome in Cardiovascular, Pulmonary
and Hematologic Health and Diseases included the need
to study (1) the role of the virome in shaping and regu-
lating immunity in health and states of inflammation in
HLB disorders, as well as the effect of immune strength
and function on the virome; (2) the role of the virome in
HLB health and diseases through its effects on endothe-
lium, coagulation, and thrombus formation, particularly
its effects on platelets, as well as effects on blood cell
growth, differentiation, and function and in blood diseases
including hereditary hematologic disorders (e.g., sickle cell
disease, thalassemia), myeloproliferative disorders, and
myelodysplastic syndromes; and (3) the role of the virome
in HLB health and diseases in the context of medical and
pharmacological interventions such as transfusion, mech-
anical intubation, immunosuppression, anti-retroviral ther-
apy, and hematopoietic stem cell transplantation (HSCT).
In the past, NHLBI has supported research on viruses
affecting blood transfusion safety and heart or lung health
[31–33]. Findings from such research and other studies
[34–37] informed policy decisions relating to strategies
that prevent transmission of viruses such as HIV and
hepatitis B or C through blood as well as cells, tissues, and
organs. However, there are many other viral elements
present in the blood which are not tested for, of which the
most recently identified Giant Blood Marseillevirus and of
anelloviruses now detected in almost all individuals are
just two examples [38–40]. Transfusion of blood to fetuses
and infants whose immune system are in development
could potentially have a profound impact on their health,
either in a positive or negative manner. It is well recog-
nized that exposure to viruses early in life could have very
different health impact compared to similar exposure
during adulthood. For example, 90 % of infants exposed to
hepatitis B virus (HBV) become chronically infected while
95 % of adults recover completely from HBV infection
[41]. Although there are as many as 40,000 transfusions
performed annually in populations younger than 1 year
old in the USA alone [42], the impact of the infused
virome on health, for example in shaping and regulating
immunity and tolerance, is largely unknown, emphasizing
the need for research in this area.
In addition to the outcome of the Working Group
described above, the NHLBI Strategic Visioning, an on-
going process dedicated to shape scientific priorities for
the Institute and guide future funding strategies over
the next decade, identified virome research as an area
for further focus. To help address this need, NHLBI de-
veloped an initiative to support studies that evaluate
how the human virome interacts with its host and the
molecular and physiological mechanisms that govern
those interactions. The funding opportunity announce-
ment (FOA), RFA-HL-17-002, entitled, “The Role of
the Human Virome in Heart, Lung, and Blood Health
and Resilience (R61/R33),” was published on October 5,
2016, with the receipt date of June 24, 2016, or for
AIDS Applications: August 9, 2016, and will award
grants in fiscal year 2017 [43]. It is hoped that this ini-
tiative will attract investigators to not only identify add-
itional virome elements but also more importantly to
understand how the human virome may affect HLB
health and resilience including potential interactions
with the immune system and its effect on inflammation.
Elucidation of such mechanisms of interaction may
help to eventually develop diagnostic and therapeutic
intervention strategies targeted to modifying the virome
and its effect on host cells. In the context of HIV infec-
tion, virome research could help unravel whether asso-
ciations between the virome, inflammation, and heart,
lung, blood, and sleep comorbidities may be influenced
by current ART regimens and timing of their initiation
upon diagnosis of HIV infection.
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